InflaRx Future Growth
Future criteria checks 2/6
InflaRx's earnings are forecast to decline at 5.9% per annum while its annual revenue is expected to grow at 71.3% per year. EPS is expected to grow by 7.7% per annum. Return on equity is forecast to be -14.8% in 3 years.
Key information
-5.9%
Earnings growth rate
7.7%
EPS growth rate
Biotechs earnings growth | 30.2% |
Revenue growth rate | 71.3% |
Future return on equity | -14.8% |
Analyst coverage | Low |
Last updated | n/a |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2024 | 14 | -43 | -40 | -35 | 4 |
12/31/2023 | 7 | -44 | -43 | -38 | 4 |
12/31/2022 | 4 | -35 | -17 | -32 | 4 |
9/30/2022 | N/A | -34 | -40 | -40 | N/A |
6/30/2022 | N/A | -38 | -47 | -47 | N/A |
3/31/2022 | N/A | -54 | -42 | -42 | N/A |
12/31/2021 | N/A | -46 | -40 | -40 | N/A |
9/30/2021 | N/A | -42 | -38 | -38 | N/A |
6/30/2021 | N/A | -37 | -37 | -37 | N/A |
3/31/2021 | N/A | -32 | -37 | -36 | N/A |
12/31/2020 | N/A | -34 | -37 | -37 | N/A |
9/30/2020 | N/A | -39 | -43 | -43 | N/A |
6/30/2020 | N/A | -46 | -43 | -43 | N/A |
3/31/2020 | N/A | -52 | -46 | -45 | N/A |
12/31/2019 | N/A | -53 | -44 | -43 | N/A |
9/30/2019 | N/A | -50 | -34 | -33 | N/A |
6/30/2019 | N/A | -42 | -30 | -29 | N/A |
3/31/2019 | N/A | -29 | -25 | -24 | N/A |
12/31/2018 | N/A | -30 | -22 | -22 | N/A |
9/30/2018 | N/A | -31 | -20 | -19 | N/A |
6/30/2018 | N/A | -29 | -19 | -18 | N/A |
3/31/2018 | N/A | -31 | -15 | -15 | N/A |
12/31/2017 | N/A | -24 | -12 | -12 | N/A |
9/30/2017 | N/A | -17 | -10 | -10 | N/A |
6/30/2017 | N/A | -15 | -8 | -8 | N/A |
3/31/2017 | N/A | -12 | -7 | -7 | N/A |
12/31/2016 | N/A | -9 | -5 | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IF0 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IF0 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IF0 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IF0's revenue (71.3% per year) is forecast to grow faster than the German market (4.6% per year).
High Growth Revenue: IF0's revenue (71.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IF0 is forecast to be unprofitable in 3 years.